Sale disclosed
Theodore Alan Huizenga
SVP, Chief Accounting Officer
Common Stock
- Reported value
- $17.41K
- Reported price
- $13.57 / share
Loading data…Scanning SEC filings…Checking Congress reports…Following the signal…
Ultragenyx Pharmaceutical Inc.
Last 30 daysNo qualifying insider buying. Sales: $17.41K by 1 insider.
Showing the first 6 of 12 trades on this page.
SVP, Chief Accounting Officer
Common Stock
SVP, Chief Accounting Officer
Common Stock
EVP and Chief Legal Officer
Common Stock
Chief Financial Officer
Common Stock
Chief Financial Officer
Common Stock
Director
Common Stock
EVP and Chief Legal Officer
Common Stock
Chief Financial Officer
Common Stock
Director
Common Stock
EVP and Chief Medical Officer
Common Stock
Chief Financial Officer
Common Stock
Chief Financial Officer
Common Stock
| Reporting insider | Security / transaction | Amount / price | Value | Traded / disclosed | Source |
|---|---|---|---|---|---|
| SVP, Chief Accounting Officer | Common StockSale10b5-1 | 1,283$13.57 / share | $17.41K | Sep 15Filed Sep 15 · 0d later | SEC filing |
| SVP, Chief Accounting Officer | Common StockSale | 161$13.99 / share | $2.25K | Sep 3Filed Sep 8 · 5d later | SEC filing |
| EVP and Chief Legal Officer | Common StockSale10b5-1 | 1,900$24.92 / share | $47.35K | Aug 3Filed Aug 4 · 1d later | SEC filing |
| Chief Financial Officer | Common StockSale10b5-1 | 4,696$24.92 / share | $117.02K | Aug 3Filed Aug 4 · 1d later | SEC filing |
| Chief Financial Officer | Common StockSale10b5-1 | 4,698$33.13 / share | $155.64K | Jul 1Filed Jul 6 · 5d later | SEC filing |
| Director | Common StockSale | 2,000$25.05 / share | $50.1K | Jun 15Filed Jun 15 · 0d later | SEC filing |
| EVP and Chief Legal Officer | Common StockSale10b5-1 | 1,899$24.62 / share | $46.75K | Jun 15Filed Jun 15 · 0d later | SEC filing |
| Chief Financial Officer | Common StockSale10b5-1 | 4,653$23.77 / share | $110.6K | Jun 1Filed Jun 1 · 0d later | SEC filing |
| Director | Common StockSale10b5-1 | 5,740$25.12 / share | $144.19K | May 18Filed May 18 · 0d later | SEC filing |
| EVP and Chief Medical Officer | Common StockSale | 344$24.96 / share | $8.59K | May 5Filed May 6 · 1d later | SEC filing |
| Chief Financial Officer | Common StockSale10b5-1 | 4,683$24.90 / share | $116.61K | May 1Filed May 4 · 3d later | SEC filing |
| Chief Financial Officer | Common StockSale10b5-1 | 4,683$20.97 / share | $98.2K | Apr 1Filed Apr 2 · 1d later | SEC filing |
Ultragenyx Pharmaceutical Inc. - Common Stock (RARE) · Stock
The filing reports a purchase for the member.
Gilbert CisnerosReporting House memberUltragenyx Pharmaceutical Inc. - Common Stock (RARE) · Stock
The filing reports a purchase for the member.
Gilbert CisnerosReporting House memberNo eligible common-equity purchase is public by this cutoff within 180 transaction-date days. Other instruments, exercises and routine activity do not contribute purchase points.
This score describes qualifying insider purchases at issuer level. Read the methodology
Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.
Insider activity can have many explanations. Signal Strength is not a probability of profit or a recommendation to trade.